Lineage Cell Therapeutics Inc Cash Flow-to-Debt Ratio
Lineage Cell Therapeutics Inc cash flow-to-debt ratio. Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of $-3.62 Million could theoretically repay 0% of its total liabilities ($68.84 Million) in one year. Check Lineage Cell Therapeutics Inc (LCTX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lineage Cell Therapeutics Inc (1991–2024)
Cash flow-to-debt ratio of Lineage Cell Therapeutics Inc from 1991 to 2024. Historical debt coverage capacity for Lineage Cell Therapeutics Inc across 34 annual periods. Check LCTX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Lineage Cell Therapeutics Inc Cash Flow-to-Debt Ratio by Year (1991–2024)
Lineage Cell Therapeutics Inc cash flow-to-debt ratio by year from 1991 to 2024. Year-by-year debt coverage analysis for Lineage Cell Therapeutics Inc. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-23.09 Million | $36.21 Million | ▲ +12.9% |
| 2023 | -0.73x | $-28.57 Million | $39.00 Million | ▼ -3678.2% |
| 2022 | 0.02x | $1.06 Million | $51.73 Million | ▲ +107.3% |
| 2021 | -0.28x | $-23.56 Million | $83.65 Million | ▲ +81.7% |
| 2020 | -1.54x | $-19.75 Million | $12.82 Million | ▲ +31.4% |
| 2019 | -2.24x | $-31.95 Million | $14.23 Million | ▲ +31.6% |
| 2018 | -3.28x | $-30.88 Million | $9.41 Million | ▲ +3.5% |
| 2017 | -3.40x | $-30.52 Million | $8.98 Million | ▲ +3.1% |
| 2016 | -3.51x | $-42.33 Million | $12.06 Million | ▼ -43.5% |
| 2015 | -2.45x | $-44.54 Million | $18.21 Million | ▲ +23.3% |
| 2014 | -3.19x | $-38.85 Million | $12.18 Million | ▼ -67.2% |
| 2013 | -1.91x | $-29.51 Million | $15.47 Million | ▲ +47.1% |
| 2012 | -3.61x | $-19.68 Million | $5.45 Million | ▼ -16.0% |
| 2011 | -3.11x | $-13.59 Million | $4.37 Million | ▼ -54.7% |
| 2010 | -2.01x | $-7.73 Million | $3.85 Million | ▼ -12.6% |
| 2009 | -1.79x | $-4.26 Million | $2.39 Million | ▼ -499.0% |
| 2008 | -0.30x | $-1.60 Million | $5.38 Million | ▲ +22.6% |
| 2007 | -0.38x | $-1.24 Million | $3.22 Million | ▲ +23.3% |
| 2006 | -0.50x | $-1.26 Million | $2.52 Million | ▲ +23.5% |
| 2005 | -0.66x | $-1.41 Million | $2.16 Million | ▲ +49.8% |
| 2004 | -1.31x | $-1.54 Million | $1.18 Million | ▼ -599.1% |
| 2003 | -0.19x | $-654.14K | $3.50 Million | ▲ +76.6% |
| 2002 | -0.80x | $-2.13 Million | $2.67 Million | ▲ +49.3% |
| 2001 | -1.57x | $-3.21 Million | $2.04 Million | ▲ +88.3% |
| 2000 | -13.50x | $-4.86 Million | $359.75K | ▼ -82.9% |
| 1999 | -7.38x | $-4.39 Million | $595.51K | ▼ -40.6% |
| 1998 | -5.25x | $-2.10 Million | $400.00K | ▼ -626.9% |
| 1997 | -0.72x | $-1.30 Million | $1.80 Million | ▲ +93.1% |
| 1996 | -10.50x | $-2.10 Million | $200.00K | ▲ +0.0% |
| 1995 | -10.50x | $-2.10 Million | $200.00K | ▼ -110.0% |
| 1994 | -5.00x | $-2.00 Million | $400.00K | ▲ +68.8% |
| 1993 | -16.00x | $-1.60 Million | $100.00K | ▼ -23.1% |
| 1992 | -13.00x | $-1.30 Million | $100.00K | ▼ -333.3% |
| 1991 | -3.00x | $-600.00K | $200.00K | — |